Information Provided By:
Fly News Breaks for June 27, 2019
ESPR
Jun 27, 2019 | 09:29 EDT
JMP Securities analyst Jason Butler said he views Esperion's funding transaction with Oberland Capital Management as a positive step for the company that provides it with optionality to optimize investment into bempedoic acid's commercial launch. The capped revenue-based funding agreement provides substantial immediate capital and strengthens the company's resources, said Butler, who maintains an Outperform rating and $153 price target on Esperion shares.
News For ESPR From the Last 2 Days
There are no results for your query ESPR
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.